Pharmacy Prior Authorization Criteria

Dojolvi (triheptanoin)

Indications for Prior Authorization

Dojolvi (triheptanoin)

• For diagnosis of Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
  Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Criteria

Dojolvi

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)

• Diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) has been confirmed by at least two of the following:
• Disease specific elevation of acyl-carnitines on a newborn blood spot or in plasma
• Low enzyme activity in cultured fibroblasts
• One or more known pathogenic mutations in CPT2, ACADVL, HADHA, or HADHB
AND
• Not used with any other medium-chain triglyceride (MCT) product
AND
• Prescribed by or in consultation with a clinical specialist knowledgeable in appropriate disease-related dietary management (e.g., geneticist, cardiologist, gastroenterologist, etc.)

Dojolvi

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)

• Prescriber attests to continued need of therapy [A]
AND
• Not used with any other medium-chain triglyceride (MCT) product
AND
• Prescribed by or in consultation with a clinical specialist knowledgeable in appropriate disease-related dietary management (e.g., geneticist, cardiologist, gastroenterologist, etc.)

P & T Revisions

2024-09-04, 2023-09-05, 2022-09-14, 2021-08-05, 2020-09-16

References

1. Dojolvi (triheptanoin) prescribing information. Ultragenyx Pharmaceutical Inc. Novato, CA. October 2023.
2. Per clinical consult with internal medicine/pediatric specialist, September 24, 2020.

---

Revision History

• 2024-09-04: 2024 Annual Review. Updated references.
• 2023-09-05: Annual Review
• 2022-09-14: Annual Review
• 2021-08-05: Annual Review
• 2020-09-16: New Program

---